Bcl?2 family: Novel insight into individualized therapy for ovarian cancer (Review).

ABSTRACT: Chemoresistance to platinum?based chemotherapy for ovarian cancer in the advanced stage remains a formidable concern clinically. Increasing evidence has revealed that apoptosis represents the terminal events of the anti?tumor mechanisms of a number of chemical drugs and has a close association with chemoresistance in ovarian cancer. The B?cell lymphoma?2 (Bcl?2) family plays a crucial role in apoptosis and has a close association with chemoresistance in ovarian cancer. Some drugs that target Bcl?2 family members have shown efficacy in overcoming the chemoresistance of ovarian cancer. A BH3 profiling assay was found to be able to predict how primed a cell is when treated with antitumor drugs. The present review summarizes the role of the Bcl?2 family in mediating cell death in response to antitumor drugs and novel drugs that target Bcl?2 family members. The application of the new functional assay, BH3 profiling, is also discussed herein. Furthermore, the present review presents the hypothesis that targeting Bcl?2 family members may prove to be helpful for the individualized therapy of ovarian cancer in clinical practice and in laboratory research.

SUBMITTER: Yuan J 

PROVIDER: S-EPMC7447322 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature